Lawrenceville, NJ, United States of America

Aaron Paul Yamniuk

This inventor holds 33 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 14 EPO patents, primarily in Antibody Engineering. Top assignees: Bristol-Myers Squibb Compnay, Domantis Limited, Cytomx Therapeutics, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aaron Paul Yamniuk. Retrieved from https://idiyas.com/inventor/aaron-paul-yamniuk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 17)

% Patents Active = 93.9

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 14 (Patent Applications = 19)

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 173(Granted Patents)

Location History:

Lawrenceville, NJ (US) (2014 - 2024)
Princeton, NJ (US) (2024)

Company Filing History:

33 out of 3,745

Bristol-Myers Squibb Compnay

Cytomx Therapeutics, Inc.

patents

4. 1 out of 751

The Rockefeller University

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Anti-CD40 Antibodies

Anti-TREM-1 Antibodies

Fibronectin Proteins

Antibody Polypeptides

IL-7R Antibodies

Immune Disease Treatment

Nucleic Acids

Monoclonal Antibodies

Tumor Necrosis Factor

Myostatin Binding

CD73 Antibodies

CD40L Antagonists

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11952427 - Anti-CD40 antibodies and uses thereof (2024-04-09),

2. 11952420 - Nucleic acids encoding anti-TREM-1 antibodies (2024-04-09),

3. 11919962 - Antibodies against IL-7R alpha subunit and uses thereof (2024-03-05),

4. 11919954 - Anti-TREM-1 antibodies and uses thereof (2024-03-05),

5. 11813315 - Fibronectin based scaffold domain proteins that bind to myostatin (2023-11-14),

6. 11512124 - Fibronectin type III domain proteins with enhanced solubility (2022-11-29),

7. 11352440 - Antibodies against CD73 and uses thereof (2022-06-07),

8. 11306149 - Anti-CD40 antibodies and uses thereof (2022-04-19),

9. 11261258 - Antagonistic CD40 monoclonal antibodies and uses thereof (2022-03-01),

10. 11254750 - Antagonistic CD40 monoclonal antibodies and uses in treating immune responses (2022-02-22),

11. 11220550 - Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity (2022-01-11),

12. 11213586 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) (2022-01-04),

13. 11180567 - Antibody polypeptides that antagonize CD40L (2021-11-23),

14. 11155618 - Anti-TREM-1 antibodies and uses thereof (2021-10-26),

15. 11136406 - Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40 (2021-10-05),

Sure, I can assist with that. Here is the article based on the data provided:

Title: Unveiling the Inventive Legacy of Aaron Paul Yamniuk

Introduction:

Aaron Paul Yamniuk, a prolific inventor based in Lawrenceville, NJ (US), has made significant contributions to the field of biotechnology with his impressive portfolio of 31 patents.

Latest Patents:

Yamniuk's latest patents include groundbreaking innovations such as:

1. Antibodies against IL-7R alpha subunit and uses thereof - These antibodies target the alpha subunit of an IL-7 receptor, showing promise in the treatment of inflammatory diseases.

2. Anti-TREM-1 antibodies and uses thereof - These antibodies inhibit TREM-1 signaling and are utilized in therapeutic applications for autoimmune diseases.

Career Highlights:

Yamniuk has lent his expertise to renowned companies such as Bristol-Myers Squibb Company and Domantis Limited, showcasing his ability to thrive in diverse and cutting-edge environments.

Collaborations:

Throughout his career, Yamniuk has collaborated with esteemed professionals in the industry, including Stanley Richard Krystek, Jr and Suzanne J Suchard, enhancing his innovative endeavors with their collective expertise.

Conclusion:

In conclusion, Aaron Paul Yamniuk's trailblazing work in the realm of biotechnology underscores his unwavering commitment to advancing scientific knowledge and improving healthcare outcomes. His inventive spirit and collaborative nature continue to inspire future generations of innovators in the field.

Is there anything else you would like to know or any specific details you would like to add to the article?

Profile summary based on public USPTO records.